Published in PLoS One on May 30, 2013
Strengthening national health laboratories in sub-Saharan Africa: a decade of remarkable progress. Trop Med Int Health (2014) 1.12
Cancer patients need better care, not just more technology. Nature (2017) 0.97
Can Unmanned Aerial Systems (Drones) Be Used for the Routine Transport of Chemistry, Hematology, and Coagulation Laboratory Specimens? PLoS One (2015) 0.96
Laboratory Diagnostics Market in East Africa: A Survey of Test Types, Test Availability, and Test Prices in Kampala, Uganda. PLoS One (2015) 0.82
Laboratory challenges conducting international clinical research in resource-limited settings. J Acquir Immune Defic Syndr (2014) 0.79
Piloting laboratory quality system management in six health facilities in Nigeria. PLoS One (2014) 0.75
A comprehensive review of the SLMTA literature part 1: Content analysis and future priorities. Afr J Lab Med (2014) 0.75
Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA (1999) 40.60
Laboratory medicine in Africa: a barrier to effective health care. Clin Infect Dis (2005) 12.59
The burden and costs of chronic diseases in low-income and middle-income countries. Lancet (2007) 8.33
The World Health Organization African region laboratory accreditation process: improving the quality of laboratory systems in the African region. Am J Clin Pathol (2010) 3.83
External quality assurance performance of clinical research laboratories in sub-saharan Africa. Am J Clin Pathol (2012) 3.07
Improving the accuracy of malaria-related laboratory tests in Ghana. Malar J (2004) 2.97
Does telling people what they have been doing change what they do? A systematic review of the effects of audit and feedback. Qual Saf Health Care (2006) 2.27
Non-communicable diseases in sub-Saharan Africa: the case for cohort studies. PLoS Med (2010) 1.88
Laboratory accreditation in Thailand: a systemic approach. Am J Clin Pathol (2010) 1.19
Effect of a controlled feedback intervention on laboratory test ordering by community physicians. Clin Chem (2003) 1.12
External quality assessment of national public health laboratories in Africa, 2002-2009. Bull World Health Organ (2012) 1.09
Quality assurance in changing times: proposals for reform and research in the clinical laboratory field. Clin Chem (1987) 0.83
Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis (2004) 5.93
Risk factors for recent HIV infection in Uganda. JAMA (2008) 4.84
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet (2009) 4.33
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis (2005) 3.59
HIV transmission risk behavior among HIV-infected adults in Uganda: results of a nationally representative survey. AIDS (2008) 3.52
Improving quality management systems of laboratories in developing countries: an innovative training approach to accelerate laboratory accreditation. Am J Clin Pathol (2010) 3.52
External quality assurance performance of clinical research laboratories in sub-saharan Africa. Am J Clin Pathol (2012) 3.07
HIV prevalence and incidence are no longer falling in southwest Uganda: evidence from a rural population cohort 1989-2005. AIDS (2008) 3.01
Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007-2008. Emerg Infect Dis (2010) 2.90
Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr (2011) 2.75
Estimating the net effect of HIV on child mortality in African populations affected by generalized HIV epidemics. J Acquir Immune Defic Syndr (2005) 2.63
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis (2005) 2.54
Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr (2004) 2.21
Multicenter evaluation of use of dried blood and plasma spot specimens in quantitative assays for human immunodeficiency virus RNA: measurement, precision, and RNA stability. J Clin Microbiol (2003) 2.20
Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol (2007) 2.14
Late postnatal transmission of HIV-1 and associated factors. J Infect Dis (2007) 2.11
Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr (2006) 1.94
Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr (2004) 1.92
HIV-1 tropism and survival in vertically infected Ugandan infants. J Infect Dis (2008) 1.83
HIV infection among men who have sex with men in Kampala, Uganda--a respondent driven sampling survey. PLoS One (2012) 1.79
Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis (2007) 1.73
Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis (2008) 1.70
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr (2005) 1.69
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS (2005) 1.58
Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health (2004) 1.56
Hepatitis B infection is highly endemic in Uganda: findings from a national serosurvey. Afr Health Sci (2009) 1.56
Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission. Clin Infect Dis (2012) 1.56
Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. BMC Pediatr (2010) 1.51
Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda. J Acquir Immune Defic Syndr (2010) 1.50
Nevirapine resistance after single dose prophylaxis. AIDS Rev (2002) 1.45
Acceptability of male circumcision for prevention of HIV infection among men and women in Uganda. AIDS Care (2011) 1.34
The estimated burden of HIV/AIDS in Uganda, 2005-2010. AIDS (2008) 1.34
Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn (2006) 1.25
Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr (2005) 1.24
Analysis of HIV diversity using a high-resolution melting assay. AIDS Res Hum Retroviruses (2010) 1.23
Association of HIV diversity and survival in HIV-infected Ugandan infants. PLoS One (2011) 1.23
Defining minimum standards of practice for incorporating African traditional medicine into HIV/AIDS prevention, care, and support: a regional initiative in eastern and southern Africa. J Altern Complement Med (2004) 1.21
Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. J Acquir Immune Defic Syndr (2007) 1.20
Noninferiority of a task-shifting HIV care and treatment model using peer counselors and nurses among Ugandan women initiated on ART: evidence from a randomized trial. J Acquir Immune Defic Syndr (2013) 1.16
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis (2002) 1.16
HIV incidence, retention, and changes of high-risk behaviors among rural injection drug users in Guangxi, China. Subst Abus (2006) 1.14
Comparison of HIV prevalence estimates from sentinel surveillance and a national population-based survey in Uganda, 2004-2005. J Acquir Immune Defic Syndr (2009) 1.14
Uganda's new national laboratory sample transport system: a successful model for improving access to diagnostic services for Early Infant HIV Diagnosis and other programs. PLoS One (2013) 1.13
Developing an evidence-based, preventive care package for persons with HIV in Africa. Trop Med Int Health (2005) 1.13
HIV incidence, retention rate, and baseline predictors of HIV incidence and retention in a prospective cohort study of injection drug users in Xinjiang, China. Int J Infect Dis (2007) 1.13
Response to antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose nevirapine at birth. J Acquir Immune Defic Syndr (2009) 1.12
Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis (2006) 1.11
HIV prevalence among injection drug users in rural Guangxi China. Addiction (2006) 1.11
Iron deficiency anemia is highly prevalent among human immunodeficiency virus-infected and uninfected infants in Uganda. J Nutr (2002) 1.09
Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda. J Acquir Immune Defic Syndr (2009) 1.08
Analysis of insertions and deletions in the gag p6 region of diverse HIV type 1 strains. AIDS Res Hum Retroviruses (2004) 1.05
Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first-line antiretroviral drugs in Uganda. BMC Infect Dis (2012) 1.05
Associations of chemokine receptor polymorphisms With HIV-1 mother-to-child transmission in sub-Saharan Africa: possible modulation of genetic effects by antiretrovirals. J Acquir Immune Defic Syndr (2008) 1.04
Analysis of HIV-1 variants by cloning DNA generated with the ViroSeq HIV-1 Genotyping System. Biotechniques (2003) 1.02
Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays. AIDS Res Hum Retroviruses (2002) 1.02
Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine. AIDS (2007) 1.02
Glycoform analysis of recombinant and human immunodeficiency virus envelope protein gp120 via higher energy collisional dissociation and spectral-aligning strategy. Anal Chem (2014) 1.02
Effect of periodic vitamin A supplementation on mortality and morbidity of human immunodeficiency virus-infected children in Uganda: A controlled clinical trial. Nutrition (2005) 1.01
Comparison of results obtained with Amplicor HIV-1 DNA PCR test version 1.5 using 100 versus 500 microliters of whole blood. J Clin Microbiol (2008) 1.00
Use of a high resolution melting assay to analyze HIV diversity in HIV-infected Ugandan children. Pediatr Infect Dis J (2012) 0.99
Antenatal vitamin A supplementation increases birth weight and decreases anemia among infants born to human immunodeficiency virus-infected women in Malawi. Clin Infect Dis (2002) 0.99
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. AIDS Res Hum Retroviruses (2009) 0.98
Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS (2002) 0.98
Considerations in using US-based laboratory toxicity tables to evaluate laboratory toxicities among healthy malawian and Ugandan infants. J Acquir Immune Defic Syndr (2010) 0.98
Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival. J Acquir Immune Defic Syndr (2013) 0.97
A modified ultrasensitive assay to detect quantified HIV-1 RNA of fewer than 50 copies per milliliter. Am J Clin Pathol (2003) 0.97
Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. Afr Health Sci (2003) 0.95
Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. J Acquir Immune Defic Syndr (2005) 0.95
Cotrimoxazole resistance of Streptococcus pneumoniae and commensal streptococci from Kampala, Uganda. Scand J Infect Dis (2009) 0.94
HIV prevalence in voluntary counseling and testing centers compared with national HIV serosurvey data in Uganda. J Acquir Immune Defic Syndr (2008) 0.94
Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr (2014) 0.93
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D. AIDS Res Hum Retroviruses (2007) 0.93
Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. Transfusion (2002) 0.92
The human immunodeficiency virus-1 genotype diversity and drug resistance mutations profile of volunteer blood donors from Chinese blood centers. Transfusion (2011) 0.92
Identification of Ugandan HIV type 1 variants with unique patterns of recombination in pol involving subtypes A and D. AIDS Res Hum Retroviruses (2002) 0.91
Multivitamin supplementation in HIV infected adults initiating antiretroviral therapy in Uganda: the protocol for a randomized double blinded placebo controlled efficacy trial. BMC Infect Dis (2012) 0.90
Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. Int J Drug Policy (2011) 0.90
Vertical transmission of X4-tropic and dual-tropic HIV-1 in five Ugandan mother-infant pairs. AIDS (2009) 0.90
Clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome in patients with tuberculosis-HIV coinfection. Antivir Ther (2012) 0.88
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J Clin Microbiol (2002) 0.87
Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq). AIDS Res Hum Retroviruses (2008) 0.87
Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda. AIDS Res Hum Retroviruses (2010) 0.87
Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission. J Infect Dis (2008) 0.87
Modelling the potential impact and cost of scaling-up male circumcision in resource poor settings: A case of Uganda. Afr J AIDS Res (2013) 0.86
Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D. J Acquir Immune Defic Syndr (2006) 0.86
Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assay. PLoS One (2010) 0.86
Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. AIDS Res Hum Retroviruses (2006) 0.85
Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration. AIDS (2010) 0.84
Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection. J Infect Dis (2003) 0.81
Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants. AIDS Res Hum Retroviruses (2009) 0.81
Distribution of haematological and chemical pathology values among infants in Malawi and Uganda. Paediatr Int Child Health (2012) 0.81